PMID- 36627994
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230112
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 14
IP  - 12
DP  - 2022 Dec
TI  - An Evidence-Based Retrospective Study for the Management of Acid Peptic Disease 
      With Omeprazole, a Proton Pump Inhibitor, in Indian Patients With Type 2 Diabetes 
      Mellitus (PRIDE-1).
PG  - e32332
LID - 10.7759/cureus.32332 [doi]
LID - e32332
AB  - Background In this study, we aimed to assess the effectiveness of omeprazole 
      therapy in the management of acid peptic disease (APD) among type 2 diabetes 
      mellitus (T2DM) patients. Methodology In this multicenter retrospective study, 
      electronic medical records (EMRs) of T2DM patients with APD who were prescribed 
      omeprazole between March 2018 and April 2021 at multiple Indian healthcare 
      settings were reviewed. The resolution of APD symptoms was assessed at visit five 
      (120 days after the index visit) and compared to visit one (index visit). Safety 
      was established in terms of reported adverse events during the study period. 
      Results Overall, 174 patients were included. The majority of patients (63.8%) 
      were males with a mean age of 48.6 +/- 11.03 years. After receiving omeprazole 
      therapy, a significant number of patients reported improvement in symptoms such 
      as abdominal pain (98.2%), epigastric burning (74.2%), altered bowel movements 
      (62.1%), and nausea (80.5%) (p < 0.001 for each). Complete resolution was 
      observed in all patients who complained about flatulence (100.0%) and loss of 
      appetite (100.0%) (p < 0.001 for each). The drug was found to be well tolerated. 
      Conclusions Omeprazole therapy was well tolerated and highly effective in 
      resolving APD symptoms among T2DM patients receiving fixed oral hypoglycemic 
      agents.
CI  - Copyright (c) 2022, Saboo et al.
FAU - Saboo, Bharat
AU  - Saboo B
AD  - Department of Diabetology, Prayas Diabetes Centre, Indore, IND.
FAU - Mulwani, Nimmi
AU  - Mulwani N
AD  - Department of Diabetology, Dr. Nimmi's Diabetes Care, Ahmedabad, IND.
FAU - Petare, Anup U
AU  - Petare AU
AD  - Medical Affairs, Dr. Reddy's Laboratories Ltd., Hyderabad, IND.
FAU - Veligandla, Krishna C
AU  - Veligandla KC
AD  - Medical Affairs, Dr. Reddy's Laboratories Ltd., Hyderabad, IND.
FAU - Pinto, Colette S
AU  - Pinto CS
AD  - Medical Affairs, Dr. Reddy's Laboratories Ltd., Hyderabad, IND.
FAU - Mane, Amey
AU  - Mane A
AD  - Medical Affairs, Dr. Reddy's Laboratories Ltd., Hyderabad, IND.
FAU - Rathod, Rahul
AU  - Rathod R
AD  - Medical Affairs, Dr. Reddy's Laboratories Ltd., Hyderabad, IND.
FAU - Kotak, Bhavesh
AU  - Kotak B
AD  - Medical Affairs, Dr. Reddy's Laboratories Ltd., Hyderabad, IND.
LA  - eng
PT  - Journal Article
DEP - 20221208
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC9825689
OTO - NOTNLM
OT  - acid peptic disease
OT  - electronic medical record
OT  - proton pump inhibitor
OT  - symptomatic relief
OT  - type 2 diabetes mellitus
COIS- The authors have declared financial relationships, which are detailed in the next 
      section.
EDAT- 2023/01/12 06:00
MHDA- 2023/01/12 06:01
PMCR- 2022/12/08
CRDT- 2023/01/11 01:45
PHST- 2022/12/08 00:00 [accepted]
PHST- 2023/01/11 01:45 [entrez]
PHST- 2023/01/12 06:00 [pubmed]
PHST- 2023/01/12 06:01 [medline]
PHST- 2022/12/08 00:00 [pmc-release]
AID - 10.7759/cureus.32332 [doi]
PST - epublish
SO  - Cureus. 2022 Dec 8;14(12):e32332. doi: 10.7759/cureus.32332. eCollection 2022 
      Dec.